Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Critical Care Medicine

Volumn 43, Issue 6, 2015, Pages 1332-1334

  Spellberg, Brad ^a   Bonomo, Robert A ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acinetobacter; antibiotics; combination therapy

Indexed keywords

CARBAPENEM; COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; EDITORIAL; EXTREME DRUG RESISTANT ACINETOBACTER BAUMANNII INFECTION; HIGH RISK PATIENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; FEMALE; MALE;

ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; FEMALE; HUMANS; MALE; MINOCYCLINE;

EID: 84937571464     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001029     Document Type: Editorial

References (22)

1. Shlaes DM, Sahm D, Opiela C, et al: Commentary: The FDA Reboot of Antibiotic Development. Antimicrob Agents Chemother 2013; 57:4605-4607
2. Infectious Diseases Society of America: White paper: Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012; 55:1031-1046
3. Park YK, Peck KR, Cheong HS, et al: Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009; 15:1325-1327
4. Tseng YC, Wang JT, Wu FL, et al: Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 59:181-190
5. Metan G, Sariguzel F, Sumerkan B: Factors infuencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20:540-544
6. Gordon NC, Wareham DW: A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63:775-780
7. Munoz-Price LS, Zembower T, Penugonda S, et al: Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: Study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010; 31:1057-1062
8. Liu C, Shih S, Wang N, et al: Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2014 Nov 11. [Epub ahead of print]
9. Nutman A, Glick R, Temkin E, et al: A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect 2014; 20:O1028-O1034
10. Kwon SH, Ahn HL, Han OY, et al: Effcacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull 2014; 37:340-346
11. Chuang YC, Cheng CY, Sheng WH, et al: Effectiveness of tigecy-cline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect Dis 2014; 14:102
12. Lee HY, Chen CL, Wu SR, et al: Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 2014; 42:1081-1088
13. Park SY, Choo JW, Kwon SH, et al: Risk factors for mortality in patients with Acinetobacter baumannii bacteremia. Infect Chemother 2013; 45:325-330
14. Lemos EV, de la Hoz FP, Einarson TR, et al: Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: Systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416-423
15. Santimaleeworagun W, Wongpoowarak P, Chayakul P, et al: Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai 2011; 94:863-870
16. Zheng YL, Wan YF, Zhou LY, et al: Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am J Infect Control 2013; 41:e59-e63
17. Spellberg B, Rex JH: The value of single-pathogen antibacterial agents. Nat Rev Drug Discov 2013; 12:963
18. Durante-Mangoni E, Signoriello G, Andini R, et al: Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349-358
19. Marchand CL, Miller LL, Halasohoris JR, et al: E5564 enhances prophylactic antibiotic effcacy in a murine model of inhalational anthrax. ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, 2013
20. Shields RK, Clancy CJ, Gillis LM, et al: Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012; 7:e52349
21. Cheng A, Chuang Y-C, Sun H-Y, et al: Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study. Crit Care Med 2015; 43:1194-1204
22. Louie A, Fregeau C, Liu W, et al: Pharmacodynamics of levofoxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: Determination of epithelial lining fuid targets. Antimicrob Agents Chemother 2009; 53:3325-3330